Literature DB >> 17301951

CD83 expression on dendritic cells and T cells: correlation with effective immune responses.

Cindy Aerts-Toegaert1, Carlo Heirman, Sandra Tuyaerts, Jurgen Corthals, Joeri L Aerts, Aude Bonehill, Kris Thielemans, Karine Breckpot.   

Abstract

Human CD83 is a marker molecule for mature dendritic cells (DC) and is also expressed on activated B and T cells. Although CD83 has been implicated in immune responses, its function on DC and T cells remains unclear. In this study, we wanted to assess the role of CD83 expressed on DC and T cells in the immune response. Down-regulation of CD83 expression on human DC through RNA interference (RNAi) results in a less potent induction of allogeneic T cell proliferation, reduced IFN-gamma secretion by established T cells and decreased capacity in the priming of functional tumor antigen-specific CD8+ T lymphocytes. In addition, CD83 mRNA-electroporated DC are stronger T cell stimulators. However, CD83 overexpression on Melan-A/MART-1-specific tumor-infiltrating lymphocytes (TIL) circumvents the need for CD83 expression on DC. Co-culture of immature DC with TIL or K562 cells overexpressing CD83 results in the production of enhanced levels of pro-inflammatory cytokines, whereas this production is less pronounced or even absent in co-cultures with non-modified TIL or K562 cells. In conclusion, we demonstrate that CD83 expression on T cells and DC modulates the immune response by activating DC and by delivering costimulatory signals for the stimulation of naive and memory T cells, respectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301951     DOI: 10.1002/eji.200636535

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  62 in total

1.  A role for anti-CD45RB monoclonal antibody treatment upon dendritic cells.

Authors:  Hui Qi; Jin-Peng Liu; Chun-Yan Deng; Han-Xin Zhou; Shao-Ping Deng; Fu-Rong Li
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

2.  Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation.

Authors:  Patricia A Toniolo; Suhu Liu; Jennifer E Yeh; Pedro M Moraes-Vieira; Sarah R Walker; Vida Vafaizadeh; José Alexandre M Barbuto; David A Frank
Journal:  J Immunol       Date:  2015-02-27       Impact factor: 5.422

3.  L Particles Transmit Viral Proteins from Herpes Simplex Virus 1-Infected Mature Dendritic Cells to Uninfected Bystander Cells, Inducing CD83 Downmodulation.

Authors:  Christiane S Heilingloh; Mirko Kummer; Petra Mühl-Zürbes; Christina Drassner; Christoph Daniel; Monika Klewer; Alexander Steinkasserer
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

4.  CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2.

Authors:  Liwen Chen; Yibei Zhu; Guangbo Zhang; Chao Gao; Weixue Zhong; Xueguang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 5.  Dendritic cell CD83: a therapeutic target or innocent bystander?

Authors:  Charlene M Prazma; Thomas F Tedder
Journal:  Immunol Lett       Date:  2007-10-29       Impact factor: 3.685

6.  Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens.

Authors:  William K Decker; Dongxia Xing; Sufang Li; Simon N Robinson; Hong Yang; David Steiner; Krishna V Komanduri; Elizabeth J Shpall
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

7.  Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes.

Authors:  Joe M Horvatinovich; Elizabeth W Grogan; Marcus Norris; Alexander Steinkasserer; Henrique Lemos; Andrew L Mellor; Irina Y Tcherepanova; Charles A Nicolette; Mark A DeBenedette
Journal:  J Immunol       Date:  2017-02-13       Impact factor: 5.422

8.  Impact of storage conditions on peripheral leukocytes transcriptome.

Authors:  Yanru Xing; Xi Yang; Haixiao Chen; Sujun Zhu; Jinjin Xu; Yuan Chen; Juan Zeng; Fang Chen; Mark Richard Johnson; Hui Jiang; Wen-Jing Wang
Journal:  Mol Biol Rep       Date:  2021-02-09       Impact factor: 2.316

Review 9.  Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.

Authors:  Alia Hdeib; Andrew Edward Sloan
Journal:  CNS Oncol       Date:  2015

10.  Therapeutic vaccines for malignant brain tumors.

Authors:  Michael P Gustafson; Keith L Knutson; Allan B Dietz
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.